Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sanofi SA (ADR) (SNY), GlaxoSmithKline plc (ADR) (GSK): This Company Is Tackling Multiple Sclerosis Head On

Page 1 of 2

Note: This article has been amended to better reflect Lemtrada’s market position.

Currently existing immunomodulatory drugs that treat Multiple Sclerosis only work to treat relapse or attacks, manage symptoms, or modify the course of the disease. MS has no cure. These drugs have too many side effects due to their lack of target specificity. Another class of drugs, recently being developed, are protein based therapies (monoclonal antibodies or mAbs) that are more target specific and cause less damage to the body. These drugs have the potential to replace the older chemical based drugs to a large extent for the huge MS market that has over 400,000 patients in the US alone. Genzyme’s Lemtrada will be among the first of these drugs to hit the market, with a recent approval in Europe. Genzyme is a subsidiary of Sanofi SA (ADR) (NYSE:SNY).

The problem with immunomodulatory drugs

Sanofi SA (ADR) (NYSE:SNY)Immunomodulatory drugs alter immune response to reduce the inflammation caused in case of MS. Existing drugs like Betaseron, Rebif, Avonex and Copaxane are used as monotherapies. Though these products are efficient in early stages to reduce the relapse rate, however, effectiveness is low in later stages of the disease. Patients with highly active RRMS have poor response to existing therapies. The side effects include infection at injection site, risk of liver toxicity and CNS disturbances.

Lemtrada advantage

Lemtrada was approved by The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the treatment of RRMS in adult patients. Lemtrada targets protein (CD52) within the immune system which is responsible for inflammatory process in MS.

The anti-inflammatory effect of Lemtrada potentially reduces relapse rate in MS. It has immediate effect on the site with minimal impact on other immune cells. Another important aspect is that unlike other therapies, it has a regime and works for longer periods. It has a novel dosing and can be administered intravenously on two treatment courses. The first course can be given for five consecutive days and then the second course will be administered for three consecutive days after 12 months. This long regime helps to control the disease over a longer period of time.

The Lemtrada development program includes CARE-MS I and CARE-MS II. CARE-MS I study is to compare Lemtrada with Rebif in patients with RRMS who are new to the treatment. The other study (CARE-MS II) is to compare Lemtrada with Rebif in patients with RRMS who have already gone through treatment measures. Both the studies have shown positive results.

Comparison

The market is highly competitive with various therapies based on different mechanism of action. In protein based therapy, Lemtrada competes with late stage therapeutic candidates such as Daclizumab, Rituximab, and Ofatumumab.

Daclizumab is a monoclonal antibody. It is developed by Biogen Idec Inc. (NASDAQ:BIIB) in collaboration with Abbott Biotherapeutics. The product binds to a molecule called CD25 on immune cells and reduces the frequency of attacks in RRMS. The product is in advanced stages (Phase III) of development. During second quarter 2013, Biogen Idec Inc. (NASDAQ:BIIB)’s total revenues were $1.7 billion, up by 21%, compared to same period last year. The growth is primarily driven by Avonex, Tysabri and Tecfidera. Avonex revenues were up by 2% YoY to $774 million, Tysabri, up by 38% to $387 million and Tecfidera’s sales were $192 million during second quarter. Adjusted EPS were $2.30, up by 26%, compared to same period in 2012.

Page 1 of 2
Loading Comments...